Editas Medicine Stock Analysis: Analyst Predicts Stock to Reach $15 - Is It Worth Buying at $5?
Thursday, 9 May 2024, 17:12
Slight Price Target Cut from a Bull
Analyst Samantha Semenkow of Citigroup reduced Editas Medicine's target price to $15 per share, remaining bullish on the stock despite the lower target.
Semenkow believes in the company's potential to improve its fundamentals significantly.
Still Lofty Potential
Semenkow highlights Editas' goal of upregulating gene expression in rare genetic diseases, foreseeing the company becoming a 'first-in-class' in certain indications.
The focus on rare blood disorders therapies could lead to favorable outcomes for investors.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.